Kristoffer S. Rohrberg

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 54 publications

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal: Journal for immunotherapy of cancer

Published: May 19, 2026

A Phase 1b/2 Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.

A Phase 1b/2 Study of Atezolizumab in Combination with Thiopurine Therapy in Patients with Metastatic Solid Tumors and Intermediate Tumor Mutational Burden.

Journal: Cancer research communications

Published: April 08, 2026

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

Journal: Journal for immunotherapy of cancer

Published: February 09, 2026

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

Rilvegostomig for Metastatic Non-Small-Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 29, 2026

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

A First-in-Human Phase I Clinical Trial Evaluating Clinical Activity and Proof of Mechanism of Tobemstomig, a PD-1-LAG-3 Bispecific Antibody, in Patients with CPI-Experienced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 21, 2025

Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform.

Immune Cell Modulation of Patient-Matched Organoid Drug Response in Precision Cancer Medicine Platform.

Journal: Cells

Published: November 13, 2025

Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids.

Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids.

Journal: Frontiers in bioengineering and biotechnology

Published: November 13, 2025

Procedures of data merging in precision cancer medicine: the PRIME-ROSE project.

Procedures of data merging in precision cancer medicine: the PRIME-ROSE project.

Journal: Acta oncologica (Stockholm, Sweden)

Published: October 17, 2025

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Phase I/II Study of AXL-Specific Antibody-Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors.

Journal: Cancer research communications

Published: September 12, 2025

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.

Journal: Neuro-oncology advances

Published: August 22, 2025

A High-Throughput ImmunoHistoFluorescence (IHF) Method for Sub-Nuclear Protein Analysis in Tissue.

A High-Throughput ImmunoHistoFluorescence (IHF) Method for Sub-Nuclear Protein Analysis in Tissue.

Journal: Cells

Published: June 17, 2025

Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access.

Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors: a roadmap to access.

Journal: Future oncology (London, England)

Published: May 09, 2025

Showing 1-12 of 54

Last Updated: 09/26/2026